Literature DB >> 1616951

Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin.

R J Kreitman1, C B Siegall, V K Chaudhary, D J FitzGerald, I Pastan.   

Abstract

Pseudomonas exotoxin (PE) is a potent cytotoxic agent that is composed of 613 amino acids arranged into three major domains. We have previously identified two positions where ligands can successfully be placed in PE to direct it to cells with specific surface receptors. One site is at the amino terminus and the other is close to but not at the C-terminus. To examine the possibility of constructing oncotoxins with two different recognition elements that will bind to two different receptors, we have placed cDNAs encoding either transforming growth factor alpha (TGF alpha) or interleukin 6 (IL6) at the 5' end of a PE gene and also inserted a cDNA encoding TGF alpha near the 3' end of the PE gene. The plasmids encoding these chimeric toxins were expressed in Escherichia coli and the chimeric proteins purified to near homogeneity. In all the new toxins, the TGF alpha near the C-terminus was inserted after amino acid 607 of PE and followed by amino acids 604-613 so that the correct PE C-terminus (REDLK) was preserved. For each chimera, the toxin portion was either PE4E, in which the cell binding domain (domain Ia) is mutated, PE40, in which domain Ia is deleted, or PE38, in which domain Ia and part of domain Ib are deleted. These derivatives of PE do not bind to the PE receptor and allow 607, 355, or 339 amino acids, respectively, between the two ligands.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616951     DOI: 10.1021/bc00013a010

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  15 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Targeted Toxin Gene Therapy Of Breast Cancer Stem Cells Using CXCR1 Promoter And bFGF 5'UTR.

Authors:  Cobra Moradian; Fatemeh Rahbarizadeh
Journal:  Onco Targets Ther       Date:  2019-10-25       Impact factor: 4.147

3.  New Life for Immunotoxin Cancer Therapy.

Authors:  Raffit Hassan; Christine Alewine; Ira Pastan
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 13.801

4.  Primary T cells for mRNA-mediated immunotoxin delivery.

Authors:  R Eggers; A Philippi; M O Altmeyer; F Breinig; M J Schmitt
Journal:  Gene Ther       Date:  2017-09-22       Impact factor: 4.184

Review 5.  A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.

Authors:  John E Weldon; Ira Pastan
Journal:  FEBS J       Date:  2011-06-02       Impact factor: 5.622

6.  The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent.

Authors:  Christopher Bachran; Matthias Schröder; Lena Conrad; Juan J Cragnolini; Fikadu G Tafesse; Laura Helming; Hidde L Ploegh; Lee Kim Swee
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.996

Review 7.  Bacterial Toxins for Cancer Therapy.

Authors:  Nour-Imene Zahaf; Gudula Schmidt
Journal:  Toxins (Basel)       Date:  2017-07-28       Impact factor: 4.546

Review 8.  Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.

Authors:  Yehudit Grinberg; Itai Benhar
Journal:  Biomedicines       Date:  2017-06-02

9.  EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway.

Authors:  Yun Yang; Ziyin Tian; Yanke Ding; Xiaojing Li; Ziheng Zhang; Liu Yang; Fangyu Zhao; Feng Ren; Rui Guo
Journal:  J Immunol Res       Date:  2018-11-25       Impact factor: 4.493

10.  EGFR-targeted Chimeras of Pseudomonas ToxA released into the extracellular milieu by attenuated Salmonella selectively kill tumor cells.

Authors:  David Quintero; Jamie Carrafa; Lena Vincent; David Bermudes
Journal:  Biotechnol Bioeng       Date:  2016-07-08       Impact factor: 4.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.